Inclusion Criteria:

- Patients must have stage IV, microscopically-confirmed carcinoma of the breast with
histologic slides and/or blocks available for review.

- Patients must have relapse or progression while receiving, or within 12 months of
having received, anthracycline-containing (doxorubicin or mitoxantrone) regimen as
either adjuvant treatment or therapy for advanced breast cancer. Prior Taxol by 3-
or 24-hour infusion is permitted. Patients who have received a maximum dose of
anthracycline (greater than 450 mg/m2) are also eligible.

- Patients must have measurable (bidimensionally) or evaluable disease.

- Patients must be 18 or more years of age.

- Patients must have a Karnofsky Performance Status greater than or equal to 70% at
screen and on the first day of treatment.

- Patients must have a life expectancy of more than 16 weeks.

- Prior irradiation is permitted, provided that prior irradiation does not exceed 25%
of the estimated bone marrow volume and provided that measurable/evaluable disease
exists outside the radiation field OR there must be histologic proof of progressive
disease within a radiation field.

- Informed consent must be obtained prior to registration.

- Patients must be more than 2 weeks from prior surgery; more than 3 weeks from
radiation therapy to the pelvis, spine or long bones; more than 3 weeks from prior
chemotherapy (more than 6 weeks for mitomycin C or nitrosureas), or more than 2 weeks
from prior hormonal therapy.

- All patients must have appropriate central venous access.

Exclusion Criteria:

Patients are excludes if their:

- Granulocyte count is less than 1,500/mm3.

- Platelet count is less than 100,000/mm3.

- Hemoglobin is less than 9 gm/dl.

- Creatinine is greater than 2.0 mg/dl.

- Total bilirubin is greater than ULN (institutional upper limit of normal)..

- SGOT (AST) and/or SGPT (ALT) is greater than 1.5 x ULN concomitant with alkaline
phosphatase greater than 2.5 x ULN.

Patients are excluded if they are:

- In visceral crisis characterized by rapidly progressive hepatic or lymphangitic lung
metastases.

- Medically unstable.

- Pregnant or lactating.

Patients are excluded if they have:

- Uncontrolled CNS disease.

- Pre-existing clinically significant peripheral neuropathy except for abnormalities
due to cancer.

- Psychological, familial, sociological or geographical conditions which do not permit
weekly medical follow-up and compliance with the study protocol.

- Prior therapy with Navelbine.

- Sensitivity to E. Coli-derived proteins.